Complement Pharma

Alexion Pharmaceuticals Inc. is continuing to search out potential novel therapies in the complement and rare diseases spaces, areas it knows well, with the latest candidates expected to come from co

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Alexion Teams With Dicerna O

Alexion Pharmaceuticals Inc. could recreate the successful model for its blockbuster complement inhibitor Soliris with another pipeline-in-a-product opportunity, through its Sept. 26 acquisition of t

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in